Download - Merck presentation
Bakry Al-kafMatteo Nebiolo Vietti
IndexAbout Merck.
Merck’s Programs.
Today’s Merck.
The Global Pharmaceutical Industry.
Financial information.
About Merckglobal research-driven pharmaceutical
company
Originally founded in 1668 in Germany.
Established in 1891 in U.S.A.
Its commitment to help all patients obtain access to the Merck medicines they need.
Merck ProgramsMerck Patient Assistance Program.
Free medicines.1.5 million prescriptions.Medicines for chronic conditions.
Merck Prescription Discount Program. For the uninsured. Saving of 15% to 20% off. Easy to access.
Merck's HIV research Program.
Merck Medical Outreach Program.
Merck's Contributionin Haiti Relief Efforts
In response to this disaster.
Initial contribution.
Donating needed medicines.
Participation on the ground.
Our Products
Vaccines Prescription Products
Animal HealthConsumer Products
From Laboratoryto Pharmacy ShelfDrug Discovery
Preclinical Testing
Investigational New Drug (IND) Application
Clinical TrialsPhase IPhase IIPhase IIIPhase IV
Approval Review
The Pharmaceutical Industry
Value Chain
Current StrategiesMerger with Schering-Plough.
Job cuts follows the merger.
Biotech medications.
acquisition. ( Merck buys Avecia)
Diversification.
Innovation.
Risks
Vioxx lawsuits issue.Withdrawn in 2004.4 billion Settlement agreement charge.
Certain of the Company’s products are going to lose patent protection.
Competitors COMPANY COUNTRY TOTAL REV M USD % R&D
Switzerland 53,324 - 13%
USA 48,371 – 1 6%
Bayer Germany 44,2 - 4%
GlaxoSmithKline United Kingdom - 42,813 - 15%
Johnson and Johnson USA 37,02 - 14%
Sanofi-Aventis France 35,645 - 16%
Switzerland 33,547 - 16%
AstraZeneca UK/Sweden 26,475 - 15%
Merck & Co. USA 22,636 - 21%
Competitors
Novar
tis
Pfize
r
Bayer
Glaxo
Smith
Kline
John
son
and
John
son
Sano
fi-Ave
ntis
Hoffm
ann–
La R
oche
Astra
Zenec
a
Merck
& C
o.
53.324
48.371
44.242.813
37.0235.645
33.547
26.475
22.636
Total Revenues (USD millions)
Total Revenues (USD millions)
Competitors
Novar
tis
Pfize
r
Bayer
Glaxo
Smith
Kline
John
son
and
John
son
Sano
fi-Ave
ntis
Hoffm
ann–
La R
oche
Astra
Zenec
a
Merck
& C
o.
0%
5%
10%
15%
20%
25%
% of revenues
Financial InformationAnnual Sales ($m)
2004 2005 2006 2007 2008 200920,500.00
21,000.00
21,500.00
22,000.00
22,500.00
23,000.00
23,500.00
24,000.00
24,500.00
22,972.80
22,011.90
22,636.00
24,197.70
23,850.30
Financial InformationMaterial and Production Cost ($m)
2004 2005 2006 2007 2008 20090.00
1,000.00
2,000.00
3,000.00
4,000.00
5,000.00
6,000.00
7,000.00
4,965.70
5,149.60
6,001.10 6,140.70
5,582.50
Financial InformationNet income as a % of sales
2004 2005 2006 2007 2008 20090.00%
5.00%
10.00%
15.00%
20.00%
25.00%
30.00%
35.00%
25.38%
21.04%19.59%
13.54%
32.74%
Current StrategiesHIV chronological disease
Despite critics referring to Robert Gallo.
We won’t follow Italian/European HIV strategy even if we could (2007).Don’t create definitive vaccine with
stem cellsWe make more money using Protease
Inhibitors
FDA faster than EU bureacracy
Same for cancer
Current Strategies
Thank youand
We are happy to answer your Questions